Skip to main content
Clinical Trials/CTRI/2023/12/060980
CTRI/2023/12/060980Not yet recruitingPhase 2

A Clinical study of Individualized Homoeopathic Medicine in improving the Social Quality of Life and Satisfaction in Generalised Anxiety Disorder.

Dr Rajikrishna R C1 site in 1 country36 target enrollmentStarted: January 3, 2024Last updated:

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Enrollment
36
Locations
1
Primary Endpoint
The outcome measurement will be done by assessing the changes using QLES-Q(sf)score

Study Overview

Brief Summary

The clinical study aims to evaluate the efficacy of Individualized Homoeopathic medicine in treating Generalized Anxiety Disorder (GAD) and enhancing social quality of life. Patients with GAD symptoms will be screened, diagnosed by a psychiatrist, and enrolled after obtaining informed consent. Detailed case assessments, routine and specific investigations, and individualized treatment plans using RADAR software and Homoeopathic Materia medica will follow. The 30C potency remedy will be administered, with adjustments based on patient progress. Regular reviews at 4-week intervals and assessments using GAD-7, Beck Anxiety Inventory, and Q-LES-Q(SF) will be conducted to measure treatment outcomes, focusing on anxiety symptom alleviation and improvements in overall quality of life and satisfaction.

Study Design

Study Type
Interventional
Allocation
Na
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • 1.Age between 18-65 years 2.Subjects of both sexes 3.Cases satisfying DSM_-5 diagnostic criteria for GAD 4.Score of Q-LES_Q(sf)≥14.

Exclusion Criteria

  • 1.Generalized Anxiety Disorder with other Psychiatric co morbidity 2.Subjects undergoing other conventional Psychiatric medication for long period 3.Subjects with other serious systemic diseases 4.Substance induced anxiety disorder 5.Pregnant and lactating women 6.At risk of self-harm or suicide.

Outcomes

Primary Outcomes

The outcome measurement will be done by assessing the changes using QLES-Q(sf)score

Time Frame: 12 months follow up. Q_LES_Q(sf)score every 3 months

Secondary Outcomes

  • The outcome measurement will be done by assessing the Beck Anxiety Inventory scale(12 month follow up, Beck Anxiety Inventory Scale every month)

Investigators

Sponsor
Dr Rajikrishna R C
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Dr Rajikrishna R C

National Homoeopathy Research Institute in Mental Health

Study Sites (1)

Loading locations...

Similar Trials